Martin Sendzik
Novartis (United States)(US)
Publications by Year
Research Areas
Protein Tyrosine Phosphatases, Galectins and Cancer Biology, Epigenetics and DNA Methylation, Synthesis and biological activity, Protease and Inhibitor Mechanisms
Most-Cited Works
- → Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer(2020)210 cited
- → Dual Allosteric Inhibition of SHP2 Phosphatase(2018)127 cited
- → Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor(2017)115 cited
- → 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors(2019)86 cited
- → Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors(2019)80 cited
- → Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase(2016)57 cited
- → Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies(2022)52 cited
- → Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-directed Serine Protease Inhibitors(2003)37 cited
- → A New Synthetic Approach to the C Ring of Known as Well as Novel Bryostatin Analogues(2003)34 cited
- → 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors(2002)33 cited